Please try another search
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Name | Age | Since | Title |
---|---|---|---|
David Fellows | 64 | 2020 | Independent Chairman |
Michael Charlton | - | - | Member of Scientific Advisor |
Jill M. Quigley | 48 | 2020 | Independent Director |
Stephen A. Harrison | - | - | Member of Scientific Advisor |
Juan Carlos Lopez-Telavera | - | - | Member of Scientific Advisor |
Hongbo Lu | 51 | 2020 | Independent Director |
Joe Shih | - | - | Member of Scientific Advisor |
Carl L. Gordon | 59 | 2018 | Independent Director |
Ann E. Taylor | 66 | 2021 | Independent Director |
Radhika Tripuraneni | 44 | 2022 | Independent Director |
Jeffrey B. Kindler | 68 | 2020 | Independent Director |
Amy L. Burroughs | 53 | 2024 | CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review